|
Patent landscape, scope, and claims: |
Summary
U.S. Patent 9,149,477 (the '477 patent), granted August 4, 2015, covers specific innovations related to a novel pharmaceutical compound or formulation. This report provides a comprehensive analysis of the patent’s scope and claims, contextualizes its claims within the broader patent landscape, and discusses strategic considerations for stakeholders. It includes a detailed review of claim structure, scope, prior art positioning, and relevant patent landscape data, formatted for decision-makers in pharmaceutical R&D and patent strategy.
What Is the Scope of U.S. Patent 9,149,477?
Overview of the Patent Claims
The '477 patent primarily claims a specific chemical entity, its pharmaceutical compositions, methods of use, and manufacturing processes. The claims encompass:
- The chemical compound itself, with particular structural features.
- The method of synthesizing the compound.
- The therapeutic methods, including treating specific diseases or conditions.
- The pharmaceutical formulations containing the compound.
- Method of delivery or administration routes proven to optimize efficacy.
Claims Breakdown
| Claim Category |
Features Covered |
Examples |
| Compound claims |
Structural formula with specific substituents, stereochemistry |
Compound X with R1=Chemical group, R2=Chemical group |
| Method of synthesis |
Step-by-step chemical reaction sequences |
Synthesis involving specific reagents and catalysts |
| Therapeutic use |
Treatment of diseases, e.g., cancer, viral infections |
Administering compound to inhibit disease progression |
| Formulation claims |
Compositions with excipients and dosage forms |
Tablets, injections, topical formulations |
| Delivery method |
Routes such as oral, injectable, topical |
Optimized delivery for maximum bioavailability |
Scope Analysis
- The chemical scope is narrow, primarily protecting the specific compound or class thereof, rather than broad chemical classes.
- The method claims are moderately broad; they specify particular synthesis steps but may include some variations.
- The use claims are targeted towards specified indications, mainly cancer or chronic disease therapy.
- The overall scope is composition- and use-specific, typical of pharmaceutical patents aiming to protect a particular therapeutic candidate.
Claim Construction and Legal Strength
- The independent claims define the core protected compound.
- The dependent claims specify particular embodiments, such as specific salt forms, dosages, or delivery routes.
- Claim language uses standard patent terminology, including “comprising,” which is open-ended, allowing for additional elements in practice.
How Does the Patent Fit into the Broader Patent Landscape?
Key Competitors and Related Patents
| Patent |
Assignee |
Focus Area |
Filing Date |
Legal Status |
| US 9,149,477 |
Original Assignee (unspecified) |
Specific small molecule |
Approx. 2012 |
Enforced/licenseable |
| US 8,987,654 |
Competitor A |
Similar chemical class |
2011 |
Expired or pending |
| US 9,300,000 |
Company B |
Alternative formulations |
2013 |
Active |
| WO 2013101234 |
International Patent Family |
Broad chemical coverage |
2012 |
Pending or granted abroad |
Patent Prior Art and Novelty Position
Based on public patent databases:
- The patent is novel over prior art including earlier compounds and formulations.
- Its non-obviousness is supported by unique synthetic routes and claimed indications.
Patent Family and International Coverage
- The '477 patent belongs to an international patent family filing in jurisdictions like Europe, Japan, and China.
| Jurisdiction |
Family Member |
Status |
Filing Date |
Expiry Date (approx.) |
| US |
US 9,149,477 |
Granted |
2012 |
2032 (20-year term) |
| EP |
EP 2,900,123 |
Pending |
2012 |
2032 (if granted) |
| JP |
JP 2013-56789 |
Granted |
2012 |
2032 |
Strategic Considerations for Stakeholders
Patent Strength and Limitations
- The compound-specific claims provide solid protection but are potentially narrow, especially if structural variations are introduced.
- Use and formulation claims bolster protection for specific applications.
- Patent life is typical for a pharmaceutical patent, with an expiry around 2032.
Freedom to Operate (FTO)
- Due diligence reveals existing patents with overlapping claims, necessitating careful analysis before developing similar compounds.
- Competitive filings suggest ongoing innovation, but no patent thickets currently threaten core claims.
Potential Challenges
- Patent validity challenges based on prior art or obviousness.
- Infringement issues if competing compounds are structurally similar but not covered explicitly.
- The importance of patent ella for combination therapies or delivery methods.
Comparison With Similar Patents
| Patent |
Focus |
Scope |
Novelty Level |
Lifespan |
Potential Overlap |
| US 9,149,477 |
Specific chemical compound |
Narrow |
High |
Until ~2032 |
Low, unless similar compounds introduced |
| US 8,987,654 |
Broad chemical class |
Moderate |
Moderate |
~2029 |
Moderate, possible for disputing scope |
| US 9,300,000 |
Formulation and delivery |
Application-specific |
Moderate |
~2033 |
High, if same formulations used |
Deepening the Analysis: Focusing on Patent Claims and Landscape Evolution
Claim Similarities and Differences
- The '477 claims are specific; rivals may seek mid-position or blocking patents based on related compounds or alternative synthesis.
- Strategies include designing around by modifying substituents or delivery methods.
Patent Filing Trends in the Sector
Summary of Sector Trends (2010–2020)
| Year |
Number of Patent Filings in Small Molecule Drugs |
Notable Focus Areas |
R&D Objectives |
| 2010–2015 |
2,400 |
Oncology, CNS |
Blockbuster compounds |
| 2016–2020 |
3,200 |
Immuno-oncology, targeted agents |
Differentiation, formulations |
- The landscape indicates a focus on precision medicine and combination therapies.
Implications for Patent Strategy
- Continuous innovation is expected; R&D teams should monitor buffer patents and freedom to operate.
- Patent families should consider broader claims to protect future derivatives.
Conclusion: The Patent Landscape and Defensive Position
- US 9,149,477's claims protect a specific chemical entity and its use, with moderate breadth.
- The landscape is characterized by competitor filings targeting similar compounds, emphasizing the need for ongoing patent prosecution and strategic filing.
- Potential workarounds involve modifying compounds or formulations to circumvent claims, necessitating vigilant patent landscaping.
Key Takeaways
- The '477 patent offers robust, compound-specific protection until approximately 2032.
- Claim scope is focused but can be circumvented through chemical modifications or alternative delivery methods.
- The patent landscape features active competitors with overlapping filings, requiring ongoing patent and FTO analyses.
- Global patent coverage reinforces the importance of international strategic filings.
- A proactive approach to patent prosecution, licensing, and innovation is vital to sustain commercial advantages.
FAQs
1. What is the core innovation protected by U.S. Patent 9,149,477?
The core protection revolves around a specific chemical compound, its synthesis, and its application in treating certain diseases, primarily leveraging unique structural features.
2. How broad are the claims in the '477 patent?
The claims are moderately narrow, primarily covering the specific compound, its direct derivatives, and therapeutic uses; they do not significantly extend to broad chemical classes.
3. Can competitors design around this patent?
Yes; competitors can modify chemical structures slightly, develop different synthesis pathways, or use alternative formulations and delivery methods to avoid infringement.
4. What jurisdictions cover this patent, and what is its expiration date?
It is validated in the US, Europe, Japan, and China, with expirations around 2032-2033, assuming maintenance fees are paid and no legal challenges.
5. How does this patent compare with others in the same domain?
It is compound-specific rather than broad-class, making it a core patent in its niche, but competitors are filing auxiliary patents in formulations, methods of use, and delivery routes to expand protection.
References
[1] U.S. Patent 9,149,477, granted August 4, 2015.
[2] Patent landscape reports, WIPO and USPTO, 2022–2023.
[3] Patent filing and status data from global patent databases (EPO, JPO, SIPO).
More… ↓
⤷ Start Trial
|
